^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    β-catenin inhibitor

    Related drugs:
    2d
    E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study. (PubMed, ESMO Open)
    In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    TP53 mutation • KRAS mutation
    |
    E7386
    3d
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
    5d
    OSU-20298: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    9d
    LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=30, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Halaven (eribulin mesylate)
    23d
    A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. (clinicaltrials.gov)
    P2, N=95, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=66 --> 95 | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Apr 2025 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Dec 2027
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Halaven (eribulin mesylate)
    24d
    ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HER-2 expression
    |
    Halaven (eribulin mesylate) • Ontruzant (trastuzumab-dttb)
    1m
    Predicting the Efficacy of Eribulin in Metastatic Breast Cancer by Assessing E-Cadherin and Vimentin Expression. (PubMed, Acta Histochem Cytochem)
    Altered E-cadherin and/or vimentin expression was more frequently observed in responders (p = 0.013) and associated with longer progression-free survival (p = 0.048). These results suggest that eribulin efficacy may be predicted by altered E-cadherin and vimentin expression before treatment.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin)
    |
    Halaven (eribulin mesylate)
    1m
    A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P1
    Phase classification
    |
    temozolomide • irinotecan • Halaven (eribulin mesylate)
    1m
    Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer. (PubMed, Cancer Med)
    These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance.
    Journal
    |
    IL6 (Interleukin 6)
    |
    doxorubicin hydrochloride • Halaven (eribulin mesylate) • Actemra IV (tocilizumab)
    1m
    Efficacy and Safety of Epalolitovorellizumab in Combination with Eribulin as Second-line and Later-line Therapy for Patients with Advanced Triple-negative Breast Cancer (ChiCTR2500111069)
    P4, N=49, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Halaven (eribulin mesylate)
    2ms
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Halaven (eribulin mesylate) • zanzalintinib (XL092)
    2ms
    Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate. (PubMed, J Control Release)
    In nonclinical evaluations, Eribulin-loaded dtNDC demonstrated potent antitumor efficacy across three xenograft models...These findings position dtNDC as a promising therapeutic combining durable tumor regression with exceptional tolerability. Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Halaven (eribulin mesylate)